Withings acquires Biosency and enters respiratory remote monitoring

Issy-les-Moulineaux / Rennes, June 22, 2026 — Withings, a leader in connected health, today announced the acquisition of Biosency, a Rennes-based company specializing in the monitoring of patients with respiratory insufficiency. With Biosency, Withings deepens its remote monitoring capabilities and reinforces its ambition to build a strong, independent European player supporting the transformation of healthcare systems.

Recognized Expertise in Respiratory Health

Founded in 2017 in Rennes, Biosency has developed a modular remote monitoring solution for patients with respiratory insufficiency and their caregivers. The solution notably includes a medically certified algorithm capable of detecting COPD exacerbations at an early stage. The company brings several years of clinical research in COPD, a certified technology, and established presence in the French healthcare system.

A Value-Creating Combination

Backed by Withings’ industrial expertise, Biosency will be able to focus on the commercialization and scaling of its solution while leveraging the Group’s broader ecosystem. Continuity of the solution, its certification, and its ongoing support for patients and healthcare professionals will be fully maintained.

"I was impressed by Biosency's medical rigor and the quality of its research in COPD. I see a strong alignment between the detection of respiratory exacerbations and the work we are doing in the monitoring of cardiometabolic diseases. This transaction is part of our ambition to build a strong and independent European player in connected health," said [Éric Carreel, President of Withings].

"Joining Withings will allow us to accelerate the deployment of our solutions while preserving the ambition that has driven Biosency since its creation: improving patient monitoring and care," added [Marie Pirotais, CEO of Biosency].

The Biosency team is joining Withings and will continue developing the solution from Rennes.

About Withings

A pioneer in everyday health monitoring, Withings created the first connected scale in 2009 and has since built an ecosystem of connected health devices, including clinically validated solutions, used by over 15 million people worldwide. Beyond measuring more than 90 biomarkers, Withings is developing a new generation of risk scores and predictive algorithms, establishing itself as a partner to the healthcare system. To learn more, visit withings.com.

About Biosency

Founded in 2017 in Rennes, Biosency develops remote monitoring solutions dedicated to patients living with chronic respiratory diseases.

Media Contact:

Jean‑François Kitten, jf@licencek.com (B2C EU)

Alma Miftari, alma@prlab.co (B2B EU)

Kate Kaminsky, withings@12080group.com (US)